Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Pfizer

Status: Completed

Conditions: Pustular Psoriasis; Psoriasis Arthropathica; Erythrodermic Psoriasis; Psoriasis Vulgaris

Treatments: Drug: Infliximab [infliximab biosimilar 3]

Study type: Observational

Funder types: Industry

Identifiers

NCT03885089

NCT03885089 (Registry Identifier)

B5371009

Details and patient eligibility

About

To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under actual status of use.

Full description

This study will be conducted with all-case investigation system in patients with psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis.

This study will be conducted in patients who used this drug after the day of approval of dosage and administration for psoriasis at contracted medical institutions. Patients who used this drug before conclusion of the contract with the medical institution will also be included in this study (retrospective patients will be included).

Therefore, Time Perspective is retrospective and prospective.

Enrollment: 10 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients with psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis who started treatment with this drug
• Patients who received this drug for the first time at the medical institution after the day of launch of this drug.

Trial design

10 participants in 1 patient group

Infliximab [infliximab biosimilar 3]

Description:

Patients with Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis treated by Infliximab BS

Treatment:

Drug: Infliximab [infliximab biosimilar 3]